Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adam R Glassman

Showing results (101-110 of 127) with videos related to

Pageof 13
Sort By:
Ophthalmology|March 4, 2016
Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical TrialJohn A Wells, Adam R Glassman, Allison R Ayala, et al.
Ophthalmology|February 9, 2024
Risk Factors for Meeting Criteria for Switching from Bevacizumab to Aflibercept When Treating Eyes with Diabetic Macular Edema and Visual Acuity of < 20/40Chirag D Jhaveri, Danni Liu, Maureen G Maguire, et al.
JAMA|December 15, 2020
Effect of Intravitreous Aflibercept vs Vitrectomy With Panretinal Photocoagulation on Visual Acuity in Patients With Vitreous Hemorrhage From Proliferative Diabetic Retinopathy: A Randomized Clinical TrialAndrew N Antoszyk, Adam R Glassman, Wesley T Beaulieu, et al.
Ophthalmology|March 20, 2010
Vitrectomy outcomes in eyes with diabetic macular edema and vitreomacular traction, Julia A Haller, Haijing Qin, et al.
JAMA|May 1, 2019
Effect of Initial Management With Aflibercept vs Laser Photocoagulation vs Observation on Vision Loss Among Patients With Diabetic Macular Edema Involving the Center of the Macula and Good Visual Acuity: A Randomized Clinical TrialCarl W Baker, Adam R Glassman, Wesley T Beaulieu, et al.
JAMA Ophthalmology|March 30, 2021
Effect of Intravitreous Anti-Vascular Endothelial Growth Factor vs Sham Treatment for Prevention of Vision-Threatening Complications of Diabetic Retinopathy: The Protocol W Randomized Clinical TrialRaj K Maturi, Adam R Glassman, Kristin Josic, et al.
JAMA|February 7, 2023
Four-Year Visual Outcomes in the Protocol W Randomized Trial of Intravitreous Aflibercept for Prevention of Vision-Threatening Complications of Diabetic RetinopathyRaj K Maturi, Adam R Glassman, Kristin Josic, et al.
Archives of Ophthalmology (Chicago, Ill. : 1960)|December 13, 2006
Diurnal variation in retinal thickening measurement by optical coherence tomography in center-involved diabetic macular edema, Ronald P Danis, Adam R Glassman, et al.
Ophthalmology|April 30, 2010
Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema, Michael J Elman, Lloyd Paul Aiello, et al.
Ophthalmology|August 5, 2008
Optical coherence tomography measurements and analysis methods in optical coherence tomography studies of diabetic macular edemaDavid J Browning, Adam R Glassman, Lloyd P Aiello, et al.
Pageof 13

Showing results (101-110 of 127) with videos related to

Sort By:
Pageof 13
Ophthalmology|March 4, 2016
Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical TrialJohn A Wells, Adam R Glassman, Allison R Ayala, et al.
Ophthalmology|February 9, 2024
Risk Factors for Meeting Criteria for Switching from Bevacizumab to Aflibercept When Treating Eyes with Diabetic Macular Edema and Visual Acuity of < 20/40Chirag D Jhaveri, Danni Liu, Maureen G Maguire, et al.
JAMA|December 15, 2020
Effect of Intravitreous Aflibercept vs Vitrectomy With Panretinal Photocoagulation on Visual Acuity in Patients With Vitreous Hemorrhage From Proliferative Diabetic Retinopathy: A Randomized Clinical TrialAndrew N Antoszyk, Adam R Glassman, Wesley T Beaulieu, et al.
Ophthalmology|March 20, 2010
Vitrectomy outcomes in eyes with diabetic macular edema and vitreomacular traction, Julia A Haller, Haijing Qin, et al.
JAMA|May 1, 2019
Effect of Initial Management With Aflibercept vs Laser Photocoagulation vs Observation on Vision Loss Among Patients With Diabetic Macular Edema Involving the Center of the Macula and Good Visual Acuity: A Randomized Clinical TrialCarl W Baker, Adam R Glassman, Wesley T Beaulieu, et al.
JAMA Ophthalmology|March 30, 2021
Effect of Intravitreous Anti-Vascular Endothelial Growth Factor vs Sham Treatment for Prevention of Vision-Threatening Complications of Diabetic Retinopathy: The Protocol W Randomized Clinical TrialRaj K Maturi, Adam R Glassman, Kristin Josic, et al.
JAMA|February 7, 2023
Four-Year Visual Outcomes in the Protocol W Randomized Trial of Intravitreous Aflibercept for Prevention of Vision-Threatening Complications of Diabetic RetinopathyRaj K Maturi, Adam R Glassman, Kristin Josic, et al.
Archives of Ophthalmology (Chicago, Ill. : 1960)|December 13, 2006
Diurnal variation in retinal thickening measurement by optical coherence tomography in center-involved diabetic macular edema, Ronald P Danis, Adam R Glassman, et al.
Ophthalmology|April 30, 2010
Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema, Michael J Elman, Lloyd Paul Aiello, et al.
Ophthalmology|August 5, 2008
Optical coherence tomography measurements and analysis methods in optical coherence tomography studies of diabetic macular edemaDavid J Browning, Adam R Glassman, Lloyd P Aiello, et al.
Pageof 13